Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

NCT00303329 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Hemosiderosis

Interventions

DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals